Abstract
Not all sarcoidosis patients need treatment. In about 40% of cases, disease will subside spontaneously. For the rest who need to be treated, older drugs like corticosteroids, methotrexate and hydroxychloroquine, as well as the more recent anti-TNF agents, will be effective in suppressing granulomatous inflammation in every organ involved in about 30% of cases. In 20% of the patients, disease will relapse upon discontinuation or tapering of treatment, and in 10% will progress (these two categories constituting chronic disease). In these cases, reinstitution of the same or alternative medication or a combination regimen is warranted. Drugs side-effects and patients comorbidities should be taken in consideration during the selection of the appropriate regimen.
Keywords: Sarcoidosis, treatment, corticosteroids, methotrexate, hydroxychloroquine, infliximab
Current Drug Therapy
Title: A Guide to Treatment of Sarcoidosis
Volume: 5 Issue: 2
Author(s): Ilias C. Papanikolaou, Hidenobu Shigemitsu and Om P. Sharma
Affiliation:
Keywords: Sarcoidosis, treatment, corticosteroids, methotrexate, hydroxychloroquine, infliximab
Abstract: Not all sarcoidosis patients need treatment. In about 40% of cases, disease will subside spontaneously. For the rest who need to be treated, older drugs like corticosteroids, methotrexate and hydroxychloroquine, as well as the more recent anti-TNF agents, will be effective in suppressing granulomatous inflammation in every organ involved in about 30% of cases. In 20% of the patients, disease will relapse upon discontinuation or tapering of treatment, and in 10% will progress (these two categories constituting chronic disease). In these cases, reinstitution of the same or alternative medication or a combination regimen is warranted. Drugs side-effects and patients comorbidities should be taken in consideration during the selection of the appropriate regimen.
Export Options
About this article
Cite this article as:
C. Papanikolaou Ilias, Shigemitsu Hidenobu and P. Sharma Om, A Guide to Treatment of Sarcoidosis, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065102
DOI https://dx.doi.org/10.2174/157488510791065102 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents Ruthenium Complexes as Anticancer Agents
Current Medicinal Chemistry Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Ligand-Based Pharmacophore Modeling, Atom-Based 3D-QSAR and Molecular Docking Studies on Substituted Thiazoles and Thiophenes as Polo-Like Kinase 1 (Plk1) Inhibitors
Combinatorial Chemistry & High Throughput Screening Telomerase Inhibitors: Potential Anticancer Agents
Mini-Reviews in Organic Chemistry Chemotherapy for Laryngeal Cancer - An Apoptotic Approach
Current Drug Targets Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects
Current Drug Metabolism Psychiatric Side Effects of Interferon Treatment
Current Drug Safety Carbonic Anhydrase Inhibitors Developed Through ‘Click Tailing’
Current Pharmaceutical Design Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Increased Production of Recombinant O-Phospho-L-Serine Sulfhydrylase from the Hyperthermophilic Archaeon Aeropyrum pernix K1 Using Escherichia coli
Current Biotechnology Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Dehydroleucodine Induces a TP73-dependent Transcriptional Regulation of Multiple Cell Death Target Genes in Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Floating Drug Delivery Systems for Prolonging Gastric Residence Time: A Review
Current Drug Delivery Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment
Current Cancer Therapy Reviews Phosphorothioate-Stimulated Uptake of siRNA by Mammalian Cells: A Novel Route for Delivery
Current Topics in Medicinal Chemistry Cadmium and Its Epigenetic Effects
Current Medicinal Chemistry Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry